1. Home
  2. DGII vs DNLI Comparison

DGII vs DNLI Comparison

Compare DGII & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$75.31

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$18.50

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGII
DNLI
Founded
1985
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.4B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
DGII
DNLI
Price
$75.31
$18.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
20
Target Price
★ $85.40
$35.75
AVG Volume (30 Days)
320.6K
★ 1.7M
Earning Date
11-11-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 77.05
N/A
EPS
★ 1.00
N/A
Revenue
★ $430,221,000.00
N/A
Revenue This Year
$23.69
N/A
Revenue Next Year
$8.72
$158.26
P/E Ratio
$72.92
★ N/A
Revenue Growth
★ 1.46
N/A
52 Week Low
$34.41
$13.75
52 Week High
$86.84
$27.30

Technical Indicators

Market Signals
Indicator
DGII
DNLI
Relative Strength Index (RSI) 53.22 40.38
Support Level $71.22 $18.07
Resistance Level $77.44 $20.84
Average True Range (ATR) 2.61 0.81
MACD 0.00 0.10
Stochastic Oscillator 85.12 43.07

Price Performance

Historical Comparison
DGII
DNLI

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: